Literature DB >> 35919530

Dual RAAS Blockade in CKD: Does the Hype have Teeth?

Jonathan S Chávez-Íñiguez1,2, Brian S Rifkin3.   

Abstract

Entities:  

Keywords:  ACE ihibitor; ARB; CKD; MRA; RAAS; aldosterone; angiotensin II; clinical nephrology; dual blockade

Mesh：

Substances：

Year:  2022        PMID： 35919530      PMCID： PMC9337902          DOI： 10.34067/KID.0000912022

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  16 in total

1.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  David Tepper
Journal:  Congest Heart Fail       Date:  2002 Jan-Feb

2.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

3.  The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.

Authors:  Valeria Saglimbene; Suetonia C Palmer; Marinella Ruospo; Patrizia Natale; Ausilia Maione; Antonio Nicolucci; Mariacristina Vecchio; Gianni Tognoni; Jonathan C Craig; Fabio Pellegrini; Giuseppe Lucisano; Jörgen Hegbrant; Rosario Ariano; Olga Lamacchia; Antonio Sasso; Susanna Morano; Tiziana Filardi; Salvatore De Cosmo; Giuseppe Pugliese; Deni A Procaccini; Loreto Gesualdo; Giuseppe Palasciano; David W Johnson; Marcello Tonelli; Giovanni F M Strippoli
Journal:  J Am Soc Nephrol       Date:  2018-11-12       Impact factor: 10.121

Review 4.  Angiotensin II receptor antagonists.

Authors:  M Burnier; H R Brunner
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

5.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

6.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Authors:  George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

7.  Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?

Authors:  A H van den Meiracker; A J Man in 't Veld; P J Admiraal; H J Ritsema van Eck; F Boomsma; F H Derkx; M A Schalekamp
Journal:  J Hypertens       Date:  1992-08       Impact factor: 4.844

8.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

10.  Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

Authors:  Rajiv Agarwal; Gerasimos Filippatos; Bertram Pitt; Stefan D Anker; Peter Rossing; Amer Joseph; Peter Kolkhof; Christina Nowack; Martin Gebel; Luis M Ruilope; George L Bakris
Journal:  Eur Heart J       Date:  2022-02-10       Impact factor: 35.855
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.